Main Article Content


Aim of the study

To evaluate the neuroprotective activity of ethanolic extract of seeds of Peganum harmala (PHEE) in wistar rat.

Materials and methods

Ethanolic extract of seeds of Peganum harmala was screened for anti-Parkinson's effect by using behavioral method, haloperidol induced catalepsy at a dose of 50 mg/kg and 100 mg/kg. Distilled water and L-dopa were employed as control and standard groups respectively.


Peganum harmala at a dose of 100 mg/kg showed maximal decrease in catalepsy (71±4.0 at 60 Minute) as compared to both negative and positive control groups.


Ethanolic extract of seeds of Peganum harmala may be useful in Parkinson's disease.


Parkinson's disease Haloperidol Peganum harmala L-dopa

Article Details

How to Cite
Abdulrahman M. Alshahrani. (2021). Evaluation of anti-Parkinson’s effect of Peganum harmala on haloperidol induced catalepsy in experimental animal model . International Journal of Research in Pharmacology & Pharmacotherapeutics, 5(3), 245-250. Retrieved from


  1. [1]. Lawrence I. Golbe. Parkinson's Disease Handbook. The American Parkinson's Disease Association, Inc. Robert Wood Johnson Medical School, New Brunswick, New Jersey. 2010, 01.
  2. [2]. Birkmayer W, Hornykiewicz O. The effect of L-3, 4-dihydroxyphenylalanine (LDOPA) on akinesia in parkinsonism. Parkinsonism Relat Disord 4, 1998, 59–60.
  3. [3]. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism: chronic treatment with L-DOPA. N Engl J Med 280, 1969, 337–45.
  4. [4]. McNaught KSP, Jenner P, Olanow CW. Protein mishandling: Role of the ubiquitin proteasome system in the pathogenesis of Parkinson’s disease. In: Jankovic J, Tolosa E, eds. Parkinson’s disease and movement disorders. Philadelphia: Lippincott Williams and Wilkins, 2007, 33–49.
  5. [5]. Pan T, Kondo S, Le W, et al. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 2008 (Epub ahead of print).
  6. [6]. Jankovic J. Pathophysiology and assessment of parkinsonian symptoms and signs. In: Pahwa R, Lyons K, Koller WC, eds. Handbook of Parkinson’s disease. New York: Taylor and Francis Group, LLC, 2007:79–104.
  7. [7]. Berardelli A, Rothwell JC, Thompson PD, et al. Pathophysiology of bradykinesia in Parkinson’s disease. Brain 124, 2001, 2131–46.
  8. [8]. Cooper JA, Sagar HJ, Tidswell P, et al. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson’s disease. Brain 117, 1994, 517–29.
  9. [9]. Giovannoni G, van Schalkwyk J, Fritz VU, et al. Bradykinesia akinesia incoordination test (BRAIN TEST): an objective computerised assessment of upper limb motor function. J Neurol Neurosurg Psychiatry 67, 1999, 624–9.
  10. [10]. Jankovic J, Schwartz KS, Ondo W. Re-emergent tremor of Parkinson’s disease. J Neurol Neurosurg Psychiatry 67, 1999, 646–50.
  11. [11]. Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord 17, 2002, 638– 44.
  12. [12]. Singh R, Pentland B, Hunter J, et al. Parkinson’s disease and driving ability. J Neurol Neurosurg Psychiatry 78, 2007, 363–6.
  13. [13]. Thomas RJ. Blinking and the release reflexes: are they clinically useful? J Am Geriatr Soc 42, 1994, 609–13.
  14. [14]. Vreeling FW, Jolles J, Verhey FRJ, et al. Primitive reflexes in healthy, adult volunteers and neurological patients: methodological issues. J Neurol 240, 1993, 495–504.
  15. [15]. Pathan Aslam R, et al. Peganum harmala: A Phyto-pharmacological Review. Inventi Rapid: Planta Activa, 2012(4), 2012, 1-2.
  16. [16]. National Research Council, Guide for the Care and Use of Laboratory animals. The National Academies Press, Washington, DC, 1996.
  17. [17]. Handbook for the Use of Animals in Neuroscience Research, 1997
  18. [18]. Organization of Economic Co-operation and Development (OECD). The OECD Guidelines for Testing of Chemical: 423 Acute Oral Toxicity, France, 2001.
  19. [19]. Litchfield JT Jr, Wilcoxon F. A simplified method of evaluating dose effect experiments. J. Pharmacol Exp. Ther. 96, 1949, 99-113.
  20. [20]. H Gerhard Vogel, Drug discovery and Evaluation- Pharmacological assays, Second edition, Springer Publication, Germany 2002, 531.
  21. [21]. Kabra MP et al, evaluation of anti-Parkinson's activity of gentisic acid in different animal models. Journal of Acute Disease. 2014, 141-144.